TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22033354
Drug: Quasi-long pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quasi-long pulse and Q-switched Nd:YAG laser treatment with topically applied carbon suspension
Study: 12390708
Drug: rhEGF ophthalmic
Normalized name: Hu-rhEGF-rP64k/Mont
DrugBank: Hu-rhEGF-rP64k/Mont (DB15781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEGF ophthalmic solution
Study: 12390708
Drug: Drug vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug vehicle (control)
Study: 9702646
Drug: Psychological preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological preparation (demonstration of materials, use of a doll, or a book with photographs)
Study: 7737255
Drug: Casodex (ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (ICI 176,334) monotherapy
Study: 16699276
Drug: Cascabel chilli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cascabel chilli (3 g daily, 880 ppm capsaicin)
Study: 16699276
Drug: Ancho chilli
Normalized name: Chilli pepper
DrugBank: Capsicum (DB10897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancho chilli (3 g daily, 488 ppm capsaicin)
Study: 15297049
Drug: Hexavalent outer
Normalized name: meningococcus B, outer membrane vesicle vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen) containing six different porin A (PorAs)
Study: 15297049
Drug: Hexavalent outer
Normalized name: meningococcus B, outer membrane vesicle vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen)
Study: 7867679
Drug: Acrivastine 24
Normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acrivastine 24 mg
Study: 7867679
Drug: Acrivastine 8
Normalized name: acrivastine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine 8 mg + pseudoephedrine 60 mg
Study: 779391
Drug: Pethidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (1 mg/kg i.v.)
Study: 779391
Drug: Anileridine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anileridine (0.25 mg/kg)
Study: 28237860
Drug: α glucosidase
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: α glucosidase inhibitor (αGI)
Study: 24894652
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg), Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Docetaxel (100 mg/m2 initially, later amended to 75 mg/m2) every three weeks for six cycles
Study: 23131911
Drug: Honey barrier
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey barrier cream
Study: 23131911
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide ointment
Study: 15751004
Drug: Encapsulated warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated warfarin (2.5 mg tablets)
Study: 15751004
Drug: Nonencapsulated warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonencapsulated warfarin (2.5 mg tablets)
Study: 12028870
Drug: Elective stenting
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective stenting using the heparin-coated beStent
Study: 10598553
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid administered orally at 25 mg/m2 and 125 mg/m2
Study: 10598553
Drug: Repetitive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive oral administration of folic acid every 6 hours
Study: 10598553
Drug: Repetitive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive oral administration of folic acid
Study: 2165860
Drug: Spectinomycin (2-gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin (2-gm single dose)
Study: 2165860
Drug: Co-trimoxazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (two tablets twice daily for seven days)
Study: 722696
Drug: Placebo systems
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo systems releasing no hormone
Study: 31150916
Drug: Brazil nut
Normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nut intake (1 Brazil nut per day, approximately 1261 μg/Se) for 2 months
Study: 27726029
Drug: Cogstate computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cogstate computerized battery assessment during the first month of induction chemotherapy
Study: 24249817
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination (Bifidobacterium infantis, Streptococcus thermophilus, and Bifidobacterium lactis, 1 × 10(9) total organisms)
Study: 3562890
Drug: one cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: one cycle of combination chemotherapy + radiation therapy + 5 cycles of combination chemotherapy
Study: 22943819
Drug: C.E.R.A. once
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. once every 4 weeks by subcutaneous administration
Study: 22943819
Drug: EPO 1-3
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO 1-3 times weekly
Study: 18386580
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI) combined with chemotherapy
Study: 18386580
Drug: Chemotherapy (CTF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CTF regimen)
Study: 31474458
Drug: Omadacycline (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omadacycline (450 mg orally every 24 h for 48 h then 300 mg orally every 24 h for 7-14 days)
Study: 31474458
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg orally every 12 h for 7-14 days)
Study: 24499441
Drug: LET 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LET 2.5 mg/day
Study: 24499441
Drug: LET 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LET 2.5 mg/day + ZOL 4 mg every 4 weeks (total of 7 infusions)
Study: 19745216
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg of hemagglutinin antigen by intramuscular injection
Study: 19745216
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg of hemagglutinin antigen by intramuscular injection
Study: 19745216
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg and 30 microg doses after the second dose
Study: 19745216
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg and 30 microg doses
Study: 17513662
Drug: Neck extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck extension (5 mL of contrast injected)
Study: 17513662
Drug: Neck flexion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck flexion (5 mL of contrast injected)
Study: 17513662
Drug: Neutral position
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral position (5 mL of contrast injected)
Study: 14759294
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of buserelin
Study: 14759294
Drug: s.c. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. administration of buserelin
Study: 9571968
Drug: 5'-DFUR 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR 600 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Study: 9571968
Drug: 5'-DFUR 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'-DFUR 800 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Study: 9571968
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of radiotherapy, 5'-DFUR and SPG
Study: 7917580
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg alendronate daily for 6 months
Study: 7917580
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg alendronate daily for 6 months
Study: 27180680
Drug: Dairy milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy milk (2 or 4 servings, 473 and 946 ml)
Study: 27180680
Drug: Water (473
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (473 ml)
Study: 20157835
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of Life Therapy (QoLT)
Study: 15480852
Drug: L-carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3 g/d)
Study: 15480852
Drug: Creatine (6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (6.75 g/d)
Study: 10493319
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride 1.5 g/d
Study: 10493319
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride 3.75 g/d
Study: 10493319
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride 3.0 g/d
Study: 8725997
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg thrice weekly
Study: 1782952
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium chloride (80 mmol.24 h‐1)
Study: 7261665
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sulindac per day
Study: 7261665
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg ibuprofen per day
Study: 25632091
Drug: Expensive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expensive placebo (subcutaneous novel injectable dopamine agonist placebo)
Study: 25632091
Drug: Cheap placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheap placebo (subcutaneous novel injectable dopamine agonist placebo)
Study: 19592632
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (premeal insulin aspart)
Study: 19592632
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and Repaglinide (in patients with IGT)
Study: 15924593
Drug: On-demand esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand esomeprazole 20 mg
Study: 15924593
Drug: Continuous esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous esomeprazole 20 mg once-daily
Study: 15924593
Drug: Continuous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ranitidine 150 mg twice-daily
Study: 12765745
Drug: Melperone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone 100 mg/day
Study: 12765745
Drug: Melperone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone 400 mg/day
Study: 12765745
Drug: Melperone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone (both doses)
Study: 6864377
Drug: 2 and
Normalized name: VITAMIN B12 AND FOLIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 and 3 hours after administration
Study: 28701205
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Art therapy and Music reminiscence)
Study: 26463607
Drug: Ulinastatin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (5,000 U/kg intravenous injection before skin incision and at the end of operation)
Study: 22920723
Drug: Porcine placental
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine placental extract (PPE) - 3 capsules/day for the first 12 weeks, then 6 capsules/day for the next 12 weeks
Study: 22920723
Drug: Toki-shakuyaku-san (TJ23)
Normalized name: San Qi
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toki-shakuyaku-san (TJ23) - control group, 24 weeks of open treatment
Study: 15842594
Drug: Sedation (meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation (meperidine 62.5 mg and midazolam 2.5 mg)
Study: 12456070
Drug: Cerebrolysin (Cere)
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (Cere) 30 ml infusion, five days/week for six weeks
Study: 12456070
Drug: Placebo infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion, five days/week for six weeks
Study: 8759491
Drug: Gold or
Normalized name: Niferex Gold Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold or methotrexate (MTX) therapy
Study: 1882158
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (specific antibiotics not mentioned)
Study: 1882158
Drug: Various antibiotics
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various antibiotics tested (specifics not mentioned)
Study: 25092393
Drug: 30-mg fimasartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg fimasartan
Study: 20308769
Drug: Cholecalciferol granules
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol granules (60,000 IU) orally once in two months (two‐monthly D₃ group)
Study: 20308769
Drug: Cholecalciferol granules
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol granules (60,000 IU) orally once a month (one‐monthly D₃ group)
Study: 20308769
Drug: Cholecalciferol granules
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol granules (60,000 IU) orally once in two months (two‐monthly D₃ group) in USES subjects
Study: 20308769
Drug: Cholecalciferol granules
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol granules (60,000 IU) orally once a month (one‐monthly D₃ group) in USES subjects
Study: 10212791
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy combined with radiotherapy
Study: 2112877
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg recombinant tissue‐type plasminogen activator (rt‐PA) intravenously over 3 hours
Study: 306577
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin
Study: 306577
Drug: Sulfonamide vaginal
Normalized name: 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfonamide vaginal cream
Study: 27594381
Drug: Probiotic Bifidobacterium
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Bifidobacterium breve BBG-001 (6.7 × 10(7) to 6.7 × 10(9) CFU per dose)
Study: 27594381
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml of one‐eighth‐strength infant formula Neocate)
Study: 18467115
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/day (Control)
Study: 15986863
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed guar gum (PHGG) 10 g/day
Study: 2071787
Drug: WEB 2086
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WEB 2086 (10 mg)
Study: 2071787
Drug: WEB 2086
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WEB 2086 (40 mg)
Study: 2071787
Drug: WEB 2086
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WEB 2086 (100 mg)
Study: 26472752
Drug: Obinutuzumab 2000
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab 2000 mg
Study: 20420663
Drug: Portal survey
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portal survey technique including semi-structured questionnaires, breath alcohol test, drug assumption tests, and reaction time measurement using a driving simulator.
Study: 18538773
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.75% ropivacaine
Study: 9333593
Drug: Potassium and
Normalized name: Potassium and/or potassium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium and magnesium treatment
Study: 3551602
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean dose, 79.6 mg per day)
Study: 3551602
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean dose, 198.4 mg per day)
Study: 30316590
Drug: 90:10 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90:10 treatment (extruded high-fat pellet mixed with low-fat control pellet)
Study: 30316590
Drug: 80:20 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80:20 treatment
Study: 30316590
Drug: 70:30 treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70:30 treatment, HFSP, and control
Study: 30316590
Drug: 90:10 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90:10 treatment
Study: 21624240
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil supplementation (0.5 g every 15 days for six times)
Study: 18056271
Drug: FPV-RTV (700/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV-RTV (700/100 mg BID) with 75% reduced RFB dose (150 mg QOD)
Study: 18056271
Drug: RFB (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFB (300 mg QD)
Study: 16416154
Drug: ximelagatran (2x36
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran (2x36 mg daily)
Study: 16416154
Drug: enoxaparin/warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin/warfarin
Study: 16416154
Drug: ximelagatran (2x24
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran (2x24 mg daily)
Study: 8449013
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral mifepristone
Study: 27663190
Drug: 1g TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g TXA intraoperative injection
Study: 22661243
Drug: 2.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/d fish oil (GA)
Study: 22661243
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d fish oil (GB)
Study: 20833940
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of orally-disintegrating olanzapine
Study: 12110113
Drug: Zolmitriptan 1
Normalized name: zolmitriptan 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 1 mg
Study: 355661
Drug: Oral bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bethanechol chloride (25 mg)
Study: 355661
Drug: Oral bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bethanechol chloride (50 mg)
Study: 355661
Drug: Oral bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bethanechol chloride (100 mg)
Study: 15114342
Drug: D-Amphetamine (AMPH)
Normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Amphetamine (AMPH) 0.25 mg/kg
Study: 8002646
Drug: Nicotinamide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide and tetracycline (500 mg nicotinamide three times daily, 500 mg tetracycline four times daily)
Study: 2562200
Drug: TAS (Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS (Y set with two short branches filled with electrolytic chloroxidizer solution)
Study: 21969261
Drug: GCQ supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCQ supplement (1200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, and 45 mg quercetin glycosides per day)
Study: 21969261
Drug: GCQ supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCQ supplement
Study: 15241585
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance (CrCl) < 65 ml/min
Study: 15241585
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance (CrCl) >= 65 ml/min
Study: 12452237
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg x kg(‐1) and succinylcholine 1.5 mg x kg(‐1) (Group LS)
Study: 12452237
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and succinylcholine 1.5 mg x kg(‐1) (Group PS)
Study: 12452237
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and rocuronium 0.6 mg x kg(‐1) (Group PR)
Study: 10352377
Drug: Mahonia aquifolium
Normalized name: Mahonia Aquifolium Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mahonia aquifolium ointment
Study: 8520743
Drug: Antacids (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (30 mL every 4 h)
Study: 8520743
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g every 4 h)
Study: 1770194
Drug: Prophylactic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic insulin
Study: 7060036
Drug: iv melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv melphalan (16 mg/m2 every 2 weeks for four doses, followed by a single dose every 4 weeks)
Study: 7060036
Drug: iv melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv melphalan (50% dose reduction)
Study: 7060036
Drug: oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral melphalan (0.15 mg/kg/day for 7 days, followed by 0.05 mg/kg/day after recovery from the wbc count nadir)
Study: 31012740
Drug: Tactile based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tactile based technology (e.g., Braille books, Braille slate and stylus)
Study: 31012740
Drug: Visual based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual based technology (e.g., video magnifiers)
Study: 25820754
Drug: Pegfilgrastim 60
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim 60 µg/kg/cycle